GenIP Plc
("GenIP" or the "Company")
Soft launch of Invention Evaluator platform
GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, announces the soft launch of its Invention Evaluator platform (‘the platform’) which is currently being trialled by several customers across Chile, Singapore, the United States and the United Kingdom.
The Invention Evaluator platform provides a single place for customers to submit inventions, receive results, compare opportunities and manage their full portfolio. GenIP combines AI-assisted research with expert analyst review while keeping clients’ confidential technology disclosures out of AI systems. This allows customers to benefit from AI-assisted assessments while protecting commercially sensitive inventions. Greater automation reduces delivery time and increases capacity, while the planned annual subscription model is expected to provide greater revenue visibility for the Company.
The platform is in early customer use, with clients across Chile, Singapore, the United States and the United Kingdom actively testing it and providing feedback ahead of the planned commercial launch in December. Customer participation provides valuable insights, helping GenIP to refine the product and practical commercialisation needs ahead of commercial launch as the Company transitions from single reports to an ongoing platform-based support model.
Harin Vaghela, Chief Product Officer, provides an overview of the new Invention Evaluator platform.
Melissa Cruz, CEO of GenIP, commented:
“We are seeing excellent progress with the customers that are currently trialling our new Invention Evaluator platform and the feedback provided is helping us to refine the model ahead of commercial launch planned for December. By moving to a subscription-based model we will have greater capacity to produce more reports and the infrastructure to covert our existing pipeline into scalable revenue.”
Watch the latest GenIP investor webinar with further information on the platform HERE.
For further information regarding GenIP, please visit www.genip.ai, or contact:
GenIP Plc Melissa Cruz, CEO |
Via Walbrook PR |
Beaumont Cornish Limited (Nominated Adviser) Roland Cornish / Asia Szusciak / Andrew Price |
Tel: +44 (0) 20 7628 3396 |
AlbR Capital Limited (Joint Broker) Colin Rowbury Jon Belliss |
Tel: +44 (0) 20 7399 9427 |
CMC Markets (Joint Broker) Douglas Crippen |
Tel: + 44 (0) 203 003 8632 |
Walbrook PR (Financial PR) Alice Woodings William Turner |
Tel: +44 (0) 7407 804 654 Tel: +44 (0) 7407 020 470 |
focusIR (Investor Relations) Kat Perez Dr Paul Cornelius |
Tel: +44 (0) 20 4570 2234 Tel: +44 (0) 20 4570 2246 |
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
Distribution: This announcement is not authorised for distribution into North America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.
About GenIP
GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
Service |
Description |
Value Proposition |
Invention Intelligence Product Suite |
AI-powered market intelligence reports assessing the commercial potential of emerging technologies |
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
IP Commercialisation Services |
End-to-end engagement to help research organisations commercialise innovations |
Provides cost-effective, broad support to achieve our clients' strategic objectives |
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
- Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
-
Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments. -
Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.